RY-023

**RY-023** is a small molecule inverse agonist selective for the α5 subunit-containing GABA-A receptors. It has demonstrated cognitive-enhancing properties and a capacity to facilitate extinction of cue-induced drug-seeking behaviors, especially in models of alcohol use disorder. RY-023 is synthesized at the University of Wisconsin-Milwaukee, primarily studied in preclinical research. Its mechanism targets GABAergic modulation, with cognitive and anti-abuse potential. Unlike nonselective GABA-A inverse agonists, RY-023’s selectivity for the α5GABA-A receptor subunit may contribute to its favorable effects on extinction learning and reduction of cue reactivity to drug-related cues[1][7][10].